Magnetic Resonance Image Guided Radiotherapy (MRIgRT) course

Key information 

Next course dates

Monday 21 to Tuesday 22 September 2026.

Location

BLB Sutton, SM2 5PT
See Sutton map at the bottom of our contacts page.

This course is organised by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

Registration 2026


Course outline

An opportunity to broaden your understanding of the capabilities and potential of MRI guidance in radiotherapy planning and treatment verification. We invite you to join us to hear from leading practitioners in the field, develop skills and share knowledge with other professionals involved in MRI in radiotherapy. 

This two day course aims to improve understanding of MRIgRT, focusing on the knowledge and skills required to support current and future needs in radiotherapy.

The development of MRI in radiotherapy planning involves close communication with radiology and radiotherapy professionals. This course is aimed at all professionals involved in or interested in MRI for radiotherapy, including radiographers, physicists and clinicians.

Course Organisers: Professor Helen McNair, Ms Erica Scurr, Dr Shaista Hafeez, Miss Trina Herbert, and Professor Uwe Oelfke 

"Great overall knowledge for all professions interested in MRI - extremely informative."
– Therapeutic Radiographer and course attendee

Course overview

The course will include taught and practical workshops to:

  • Improve understanding of the basic principles of MRI
  • Build foundation skills to support the increase in demand for MRI simulation
  • Develop practical skills
  • Learn about current clinical pathways and the latest research developments 

The practical demonstrations will include: 

  • MR simulation, image acquisition and interpretation, RT set up and safety. 
  • Sequence and parameter manipulation 
  • Adaptive workflow on the MR Linac 

Provisional lecture list 

  • The clinical need for MR in radiotherapy
  • Image contrast, Resolution and Factors affecting signal-to-noise
  • MR Simulation
  • MR planning workflow
  • MR-CT fusion planning
  • Image fusion and dosimetry
  • Safety considerations
  • Regional MR in RT – Pelvis,
  • Regional MR in RT, Abdomen (liver and pancreas)
  • Regional MR in RT, Breast
  • Managing motion (4D)
  • MR in Brachytherapy
  • MR Linac QA
  • Diffusion Weighted Imaging (DWI) principles and applications
  • Functional imaging

Draft Programme 2026

Previous comments from attendees

“I have now significantly more knowledge of potential for MRI in radiotherapy, its benefits and drawbacks.”  – Clinical Oncologist

“MRI in radiotherapy planning is a lot more complicated than I thought. Highlighted that we would be crazy to do more MRI without an MRI physicist in the trust.”  – Radiotherapy Physicist

“Excellent overview of MRI and how it is and will be used in the future.” – Radiotherapy Physicist

“Collaboration between diagnostic and Therapy radiographers is vital in MR planning.”  – Therapeutic Radiographer

IPEM approved logoCPD now logo

Accommodation

Accommodation is available in local hotels, details can be supplied upon request. 

Further information

For further details on up to date course content call +44 (0)20 8661 3704 or email Cheryl Taylor.

Latest ICR News

Image of immunofluorescence staining of bladder tumour tissue. Some areas appear lighter green, some dark blue, and others black.
Immunotherapy boost can spare more bladder cancer patients major surgery

02/06/26

An immunotherapy helps bladder cancer patients remain cancer free and enables them to avoid surgery, a phase II trial has found.
See full story
Histopathologic image illustrating squamous cell carcinoma.
Immunotherapy injection shrinks tumours in patients with recurrent and/or metastatic head and neck cancer

31/05/26

A targeted cancer treatment given via a simple injection under the skin shrank tumours in more than one third of patients with recurrent and/or metastatic head and neck cancer whose disease has stopped responding to standard treatments, according to research led by scientists at The Institute of Cancer Research, London
See full story
Image of pill bottle with pills spilling out
New targeted therapy shrinks advanced gastrointestinal tumours for 61 per cent of patients in an early study

30/05/26

A new, targeted cancer therapy for advanced gastrointestinal stromal tumours (GIST) has shown promising early results, with 61 per cent of patients who received velzatinib as first-line treatment experiencing tumour shrinkage of 30 per cent or over. The results could pave the way for a larger trial to evaluate this therapy as a first-line alternative to imatinib, which has been the standard treatment for more than two decades.
See full story
Big Bang moment in bowel cancer research
Targeted therapy shows promise for patients with advanced colorectal cancer in a first-in-human study

30/05/26

A targeted antibody therapy combined with standard chemotherapy has shown early signs of tumour shrinkage and disease control in patients with advanced bowel cancer, according to new Phase I clinical trial results from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
See full story